Huawei unveils Watch D3, highlights diabetes research at Dubai event
The company showcased its latest wearable health technology and research collaborations during the ISH-ECS 2026 conference
26 October, 2026
TT
16
Huawei has showcased its latest wearable healthcare technologies, including the new HUAWEI WATCH D3 blood pressure monitoring smartwatch, at its MEA Tech Innovation Talks conference in Dubai.
Held at Grand Plaza Mövenpick alongside the ISH-ECS 2026 annual conference, the event brought together healthcare researchers and technology experts to discuss advances in cardiovascular monitoring, early diabetes risk identification and wearable medical technology.
The ISH-ECS conference, held in Dubai from October 22 to 25, focused on developments in hypertension prevention and management.
Huawei, a member of the International Society of Hypertension (ISH), presented research involving its WATCH D Series devices and their potential applications in blood pressure monitoring.
Huawei Watch D3 targets cardiovascular monitoring
The newly introduced HUAWEI WATCH D3 incorporates blood pressure monitoring capabilities designed to make regular measurements more accessible through wearable technology.
Researchers at the event discussed how wearable devices could support hypertension management by enabling monitoring outside conventional clinical settings.
Professor Jiguang Wang, Professor of Cardiovascular Medicine at the Shanghai Institute of Hypertension, highlighted the potential of the technology.
“Innovations like Minimally Disruptive ABPM and environmental monitoring reminder by Huawei Watch D3 may be inspiring for shaping a new direction on how future blood pressure management is automated and seamlessly embedded into daily life, via wearable devices,” he stated.
Professor George Stergiou, President of the International Society of Hypertension, described the WATCH D3 as a wearable device capable of providing insights into blood pressure patterns.
He also noted that the European Society of Hypertension and ISH encourage the clinical use of validated wrist-cuff blood pressure monitors, while emphasising the need for further research into their use in clinical practice.
Huawei has also established a Wearable Blood Pressure Technology Innovation Fund in collaboration with ISH to support further hypertension research.
Huawei and Dubai Health collaborate on diabetes research
The conference also highlighted Huawei’s work in using wearable technology to support earlier identification of diabetes risk.
Professor Maryam Al Saeed of Mohammed Bin Rashid University of Medicine and Health Sciences outlined an ongoing research collaboration between Dubai Health and Huawei.
“Dubai Health and Huawei are collaborating on a clinical research initiative to evaluate non-invasive wearable technology for earlier diabetes risk, leveraging real-world health data to advance personalised prevention, enable proactive healthcare, and improve long-term health outcomes across diverse populations.”
The research forms part of broader efforts to explore how wearable devices and health data could support preventive healthcare and personalised risk assessment.
Professor Datin Yook-Chin Chia, Professor and Senior Consultant at Sunway University in Malaysia, also discussed how reducing disruption and the number of measurements required could make ambulatory blood pressure monitoring more practical for patients.
Huawei invests $28.62bn in research and development
Huawei said it invested $28.62bn in research and development (R&D) in 2025, equivalent to 21.8 per cent of its annual revenue.
The company highlighted its global health research laboratories and collaborations with medical institutions as part of its efforts to develop wearable healthcare technologies.
Beyond health monitoring, Huawei also showcased developments in its smartphone business, including foldable devices and mobile camera technology.
Edwin You, Chief Technology Officer at Huawei, presented the company’s Tau Law technology, a proposed approach to semiconductor development that focuses on reducing signal propagation delays rather than relying solely on smaller transistor dimensions.
According to Huawei, the technology uses approaches such as LogicFolding to potentially improve transistor density and system performance.
The Dubai event highlighted Huawei’s efforts to expand its presence in digital healthcare while continuing to invest in smartphone and semiconductor technologies.


















